EDGEMOND JAMES sold $4.7M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 8,750 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $538.15 ($534.06–$541.25, $4.71M total) across 8 trades on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A senior executive sold shares totaling $4.71M across multiple trades at ~$534–$541/share; the presence of a pre-arranged 10b5-1 plan reduces interpretive weight.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing.
What to watch
The article provides only the sale details; it does not include any concurrent buys, guidance changes, or new company fundamentals that would reframe the signal.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics (UTHR).
Ticker impact
United Therapeutics CFO and treasurer Edgemond James sold $4.71M of UTHR shares via an open-market sale under a 10b5-1 plan on 2026-06-22.
Likely limited near-term impact; any effect should fade unless accompanied by other negative catalysts.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational/regulatory news in the text.
Market effects
No sector read-through; this is company-specific insider liquidity activity.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, the market may overreact; the transaction may not reflect bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Company whose shares were sold by an insider under a 10b5-1 plan.
- insiderEdgemond James
CFO and treasurer who executed the open-market sale.
- trading mechanism10b5-1 plan
Pre-arranged plan that typically makes insider-sale signals less informative.
